scholarly journals Mutation of the Stargardt Disease Gene (ABCR) in Age-related Macular Degeneration

Retina ◽  
1998 ◽  
Vol 18 (2) ◽  
pp. 190
Author(s):  
R. Allikmets ◽  
N. F. Shroyer ◽  
N. Singh ◽  
J. M. Seddon ◽  
R. A. Lewis ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Disease Gene ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related

Analysis of the stargardt disease gene (ABCR) in age-related macular degeneration☆

Ophthalmology ◽  
1999 ◽  
Vol 106 (8) ◽  
pp. 1531-1536 ◽  
Author(s):  
Monica A. De La Paz ◽  
Vanessa K. Guy ◽  
Suzanne Abou-Donia ◽  
Ruth Heinis ◽  
Bekki Bracken ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Disease Gene ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related

scholarly journals Computational Quantification of Complex Fundus Phenotypes in Age-Related Macular Degeneration and Stargardt Disease

2011 ◽  
Vol 52 (6) ◽  
pp. 2976 ◽  
Author(s):  
Gwenole Quellec ◽  
Stephen R. Russell ◽  
Todd E. Scheetz ◽  
Edwin M. Stone ◽  
Michael D. Abràmoff
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related

scholarly journals Healthcare Cost of Stargardt Disease

2020 ◽  
Author(s):  
Kanza Aziz ◽  
Bonnielin K. Swenor ◽  
Joseph K. Canner ◽  
Mandeep S. Singh
Keyword(s):  
Macular Degeneration ◽  
Healthcare Cost ◽  
Financial Burden ◽  
Age Related Macular Degeneration ◽  
Administrative Claims ◽  
Direct Healthcare Cost ◽  
Stargardt Disease ◽  
Cross Sectional ◽  
Patient Cost ◽  
Age Related

AbstractImportanceStargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail.ObjectiveTo estimate the direct healthcare cost of SD.DesignCross-sectional analysis of healthcare claims.ParticipantsPatients with an ICD-9 diagnosis code of SD, non-exudative age-related macular degeneration (AMD), or bilateral sensorineural hearing loss (SHL).MethodsOutpatient administrative claims data from the IBM® MarketScan® Commercial Claims and Encounters Database from 2010 to 2014 were analyzed.Main Outcome MeasureAnnual per-patient direct healthcare cost.ResultsA total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71) was higher than that of SHL (median: $51.01, IQR: $25.66-$121.66, p <0.001) and AMD (median: $76.20, IQR: $38.00-$164.86, p <0.001). When adjusted for covariates, the annual payment for SD was $47.83 higher than SHL (p<0.001) and $17.34 higher than AMD (p<0.001).Conclusions and RelevanceThere is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.

scholarly journals Mechanism of All-trans-retinal Toxicity with Implications for Stargardt Disease and Age-related Macular Degeneration

2011 ◽  
Vol 287 (7) ◽  
pp. 5059-5069 ◽  
Author(s):  
Yu Chen ◽  
Kiichiro Okano ◽  
Tadao Maeda ◽  
Vishal Chauhan ◽  
Marcin Golczak ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Toxicity ◽  
Age Related Macular Degeneration ◽  
Stargardt Disease ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document